Although limited quantities of SfA-mc prevented further exploration of the separation of these effects, therapeutic targeting of cyclophilins by nonimmunosuppressive analogs derived from SfA and CsA, previously developed as antivirals (50), has been shown to have antifibrotic effects in the CCl4 model of liver fibrosis and in a mouse model of nonalcoholic steatohepatitis (NASH) (47, 48, 51). The gene discussed is PPIB; the disease is metabolic dysfunction-associated steatohepatitis.